Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $15.60

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have received an average rating of “Moderate Buy” from the five analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $15.60.

A number of research analysts recently issued reports on BCRX shares. Needham & Company LLC reiterated a “buy” rating and issued a $14.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Barclays boosted their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of BCRX. Deerfield Management Company L.P. Series C lifted its stake in BioCryst Pharmaceuticals by 62.9% in the second quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock valued at $50,279,000 after buying an additional 3,140,804 shares during the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of BioCryst Pharmaceuticals by 528.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 1,112,232 shares of the biotechnology company’s stock valued at $6,874,000 after acquiring an additional 935,132 shares during the period. Fisher Asset Management LLC raised its position in BioCryst Pharmaceuticals by 16.9% in the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock valued at $25,369,000 after purchasing an additional 481,359 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in BioCryst Pharmaceuticals by 472.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 496,784 shares of the biotechnology company’s stock worth $3,776,000 after purchasing an additional 409,938 shares during the period. Finally, Principal Financial Group Inc. grew its position in BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after purchasing an additional 375,890 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Trading Down 0.1 %

NASDAQ:BCRX opened at $7.52 on Friday. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $8.88. The firm has a market cap of $1.56 billion, a PE ratio of -12.33 and a beta of 1.79. The stock has a fifty day moving average price of $7.63 and a 200 day moving average price of $7.49.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $117.10 million during the quarter, compared to analysts’ expectations of $113.99 million. During the same quarter in the previous year, the business posted ($0.19) EPS. The business’s quarterly revenue was up 35.1% compared to the same quarter last year. Equities analysts forecast that BioCryst Pharmaceuticals will post -0.38 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.